c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi

Melanoma Research

Volumn 6, Issue 1, 1996, Pages 25-30

  Ohashi, A ^a   Funasaka, Y ^a   Ueda, M ^a   Ichihashi, M ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Aberrant growth; Acral lentiginous melanoma; C KIT; Dysplastic naevus; Keratinocyte melanocyte network; Tumour progression

Indexed keywords

ONCOPROTEIN;

ARTICLE; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; ONCOGENE C KIT; PRIORITY JOURNAL; TUMOR GROWTH;

BLOTTING, WESTERN; CELLS, CULTURED; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MELANOCYTES; MELANOMA; NEVUS; PROTO-ONCOGENE PROTEINS C-KIT; REFERENCE VALUES; SKIN; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030039985     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199602000-00004     Document Type: Article

References (40)

1. Chabot B, Stephenson DA, Chapman VM, et al. The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335; 88-89.
2. Nocha K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice evidence for an impaired c-kit kinase in mutant mice. Genes Development 1989; 3: 816-826.
3. Nishikawa S, Kusakabe M, Yoshinaga K, et al. In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 1991; 10: 2111-2118.
4. Fleishman RA, Saltman DL, Statny V, et al. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci USA 1991; 88: 10885-10889.
5. Spritz RA, Droetto S, Fukushima Y. Deletion of the KIT and PDGFRA genes in a patient with piebaldism. Am J Med Genet 1992; 44: 492-495.
6. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 1991; 88: 8696-8699.
7. Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 1992; 50: 261-269.
8. Spritz RA, Holmes SA, Ramesar R, et al. Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism. Am J Med Genet 1992; 44: 492-495.
9. Fleischman RA. Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene. J Clin Invest 1992; 89: 1713-1717.
10. Spritz RA, Holmes SA, Itin P, et al. Novel mutation of the kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. J Invest Dermatol 1993; 101: 22-25.
11. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235-248.
12. Qiu F, Ray P, Brown K, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988; 7: 1003-1011.
13. Funasaka Y, Boulton T, Cobb M, et al. C-kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is downregulated in melanomas. Mol Biol Cell 1992; 3: 197-209.
14. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992; 7: 51-56.
15. Zakut R, Pepris R, Eliyahu S, et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993; 8: 2221-2229.
16. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142: 339-346.
17. Rygaard K, Nakamura T, Thomsen MS. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993; 67: 37-46.
18. Inoue M, Kyo S, Fujita M, et al. Coexpression of the c-kit receptor and stem cell factor in gynecological tumors. Cancer Res 1994; 54: 3049-3053.
19. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-6143.
20. Natali PG, Nicotra MR, Sures I, et al. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992; 52: 713-717.
21. Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992; 52: 197-201.
22. Worm M, Reichert U, Dippel E, et al. Expression of growth factor receptors on human melanoma cells: comparison of modulating effects of interferons and retinoids. Exp Dermatol 1993; 2: 217-223.
23. Tohda S, Yang GS, Ashman LK, et al. Relationship between c-kit expression and proliferation in acute myeloblastic leukemia cell lines. J Cell Physiol 1993; 154: 410-418.
24. Elder DE. The dysplastic nevus. Pathology 1985; 17: 291-297.
25. Grabbe J, Welker P, Dippel E, et al. Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res 1994; 287: 78-84.
26. Longley BJ, Morganroth GS, Tyrrell LBA, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1994; 328: 1302-1307.
27. Mancianti ML, Herlyn M, Weil D, et al. Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol 1988; 90: 134-141.
28. Kishikawa T. Culture of nevus Ota Cells (in Japanese). In: Hirayama S, ed. How to Diagnose and Treat Moles. Tokyo: Bunkodo, 1994; 89-102.
29. Suter L, Brüggen J, Bröcker EB, et al. A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int J Cancer 1985; 35: 787-791.
30. Maeda K, Jimbow K. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes. Cancer 1987; 57: 415-423.
31. Welham MJ, Schrader JW. Modulation of c-kit mRNA and protein by hematopoietic growth factors. Mol Cell Biol 1991; 11: 2901-2904.
32. Sillaber C, Strobl H, Bevec D, et al. IL-4 regulates c-kit protooncogene product expression in human mast and myeloid progenitor cells. J Immunol 1995; 141: 4224-4228.
33. Plummer H, Catlett J, Leftwich J, et al. C-myc-expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 1993; 53: 4337-4342.
34. Parmiter AH, Nowall PC. Cytogenetics of melanocytic tumors. J Invest Dermatol 1993; 100: 254S-258S.
35. Köck A, Schwarz T, Micksche M, et al. Cytokines and human malignant melanoma immuno- and growth-regulatory peptides in melanoma biology. In: Nathanson L ed. Melanoma Research: Genetics, Growth factors, Metastasis, and Antigens. Kluwer Academic Publishers, 1991; 41-66.
36. Ueda M, Funasaka Y, Ichihashi M, et al. Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma. Br J Dermatol 1994; 130: 320-324.
37. Bröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol 1991; 96: 662-665.
38. Fleming MG, Howe SF, Candel AG. Immunohistochemical localization of cytokines in nevi. Am J Dermatopathol 1992; 14: 496-503.
39. Asano Y, Brach MA, Ahlers A, et al. Phorbol ester 12-o-tetradecanoylphorbol-13-acetate down-regulates expression of the c-kit proto-oncogene product. J Immunol 1993; 151: 2345-2354.
40. Ling V, Chambers AF, Harris JF, et al. Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev 1985; 4: 173-194.